Ubs Group Ag Novo Cure LTD Transaction History

Ubs Group Ag

$452 Billion
Q3 2024

A detailed history of Ubs Group Ag transactions in Novo Cure LTD stock. As of the latest transaction made, Ubs Group Ag holds 200,000 shares of NVCR stock, worth $3.37 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

200,000

Previous 267,627 25.27%

Holding current value

$3.37 Million

Previous $4.58 Million 31.81%

% of portfolio

0.0%

Previous 0.0%

31 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$15.61 - $23.34 $3.99 Million - $5.97 Million	-255,748 Reduced 62.27%	154,970 $2.42 Million
Q2 2024 Aug 13, 2024	BUY	$11.83 - $24.05 $769,588 - $1.56 Million	65,054 Added 18.82%	410,718 $7.04 Million
Q1 2024 May 13, 2024	BUY	$12.42 - $17.29 $4.08 Million - $5.68 Million	328,760 Added 1944.87%	345,664 $5.4 Million
Q4 2023 Feb 09, 2024	BUY	$11.13 - $15.78 $135,708 - $192,405	12,193 Added 258.82%	16,904 $252,000
Q3 2023 Nov 09, 2023	SELL	$16.15 - $42.35 $96,221 - $252,321	-5,958 Reduced 55.84%	4,711 $76,000
Q2 2023 Aug 11, 2023	SELL	$40.29 - $82.51 $147,259 - $301,574	-3,655 Reduced 25.52%	10,669 $442,000
Q1 2023 May 12, 2023	SELL	$56.44 - $118.81 $11,344 - $23,880	-201 Reduced 1.38%	14,324 $861,000
Q4 2022 Feb 08, 2023	BUY	$63.98 - $85.37 $295,715 - $394,580	4,622 Added 46.67%	14,525 $1.07 Million
Q3 2022 Nov 10, 2022	BUY	$67.99 - $89.57 $201,794 - $265,843	2,968 Added 42.8%	9,903 $753,000
Q2 2022 Aug 10, 2022	SELL	$56.6 - $89.9 $110,087 - $174,855	-1,945 Reduced 21.9%	6,935 $482,000
Q1 2022 May 16, 2022	SELL	$60.15 - $84.52 $165,773 - $232,937	-2,756 Reduced 23.69%	8,880 $736,000
Q4 2021 Feb 14, 2022	BUY	$75.08 - $121.99 $147,832 - $240,198	1,969 Added 20.37%	11,636 $874,000
Q3 2021 Nov 15, 2021	SELL	$116.17 - $194.55 $410,196 - $686,956	-3,531 Reduced 26.75%	9,667 $1.12 Million
Q2 2021 Aug 13, 2021	SELL	$130.4 - $225.58 $5.5 Million - $9.52 Million	-42,185 Reduced 76.17%	13,198 $2.93 Million
Q1 2021 May 12, 2021	BUY	$124.11 - $190.17 $187,902 - $287,917	1,514 Added 2.81%	55,383 $7.32 Million
Q4 2020 Feb 11, 2021	BUY	$112.16 - $174.14 $2.92 Million - $4.53 Million	26,007 Added 93.34%	53,869 $9.32 Million
Q3 2020 Nov 12, 2020	BUY	$58.05 - $111.31 $1.14 Million - $2.19 Million	19,681 Added 240.57%	27,862 $3.1 Million
Q2 2020 Jul 31, 2020	SELL	$57.2 - $74.41 $3.17 Million - $4.12 Million	-55,435 Reduced 87.14%	8,181 $485,000
Q1 2020 May 01, 2020	SELL	$57.05 - $95.75 $4.48 Million - $7.53 Million	-78,602 Reduced 55.27%	63,616 $4.28 Million
Q4 2019 Feb 14, 2020	BUY	$68.3 - $93.8 $4.27 Million - $5.86 Million	62,517 Added 78.44%	142,218 $12 Million
Q3 2019 Nov 14, 2019	BUY	$61.86 - $97.8 $2.53 Million - $4.01 Million	40,953 Added 105.69%	79,701 $5.96 Million
Q2 2019 Aug 14, 2019	BUY	$42.22 - $63.23 $1.61 Million - $2.41 Million	38,045 Added 5411.81%	38,748 $2.45 Million
Q1 2019 May 14, 2019	SELL	$31.96 - $56.12 $42,315 - $74,302	-1,324 Reduced 65.32%	703 $34,000
Q4 2018 Feb 14, 2019	SELL	$28.72 - $52.63 $546,053 - $1 Million	-19,013 Reduced 90.37%	2,027 $68,000
Q3 2018 Nov 14, 2018	SELL	$32.0 - $52.4 $198,240 - $324,618	-6,195 Reduced 22.75%	21,040 $1.1 Million
Q2 2018 Aug 14, 2018	BUY	$19.85 - $32.0 $345,906 - $557,632	17,426 Added 177.65%	27,235 $853,000
Q1 2018 May 15, 2018	BUY	$19.3 - $23.65 $149,806 - $183,571	7,762 Added 379.19%	9,809 $214,000
Q4 2017 Feb 14, 2018	SELL	$16.3 - $21.9 $98,957 - $132,954	-6,071 Reduced 74.78%	2,047 $41,000
Q3 2017 Nov 14, 2017	SELL	$18.05 - $21.75 $8,988 - $10,831	-498 Reduced 5.78%	8,118 $161,000
Q2 2017 Aug 14, 2017	BUY	N/A	4,630 Added 116.16%	8,616 $149,000
Q1 2017 Nov 14, 2017	BUY	N/A	3,986	3,986 $32,000

Others Institutions Holding NVCR

# of Institutions

262

Shares Held

77M

Call Options Held

1.17M

Put Options Held

318K

View Full List

About NovoCure Ltd

Ticker NVCR
Exchange NASDAQ
Sector Healthcare
Industry Medical Instruments & Supplies
Shares Outstandng 104,950,000
Market Cap $1.77B
Description
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optu...

More about NVCR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account